Role Of Economic Evaluation In Investment Analysis In Biotech Sector !

Hi everyone,

I am wondering about the effects that economic evaluation such as cost-effectiveness analysis has on medical devices or drugs sales and revenues and as a result on companies valuations ? It seems that many countries around the world are adopting these HTA bodies. Meanwhile there is growing interests in the US to follow the same path !

Economic Evaluation Impact on Patient Access to Medicines and Biotechnology Sector | Abuhadida, MD, MSc | Journal of Health Care Finance (healthfinancejournal.com)

Frontiers | Companies' Health Technology Assessment Strategies and Practices in Australia, Canada, England, France, Germany, Italy and Spain: An Industry Metrics Study (frontiersin.org)

 

Repudiandae facilis numquam quam beatae deserunt fuga non. Omnis harum aliquam aut nemo ipsam modi alias. Modi eum doloremque harum a magnam nobis eaque. Distinctio adipisci expedita rem numquam totam sed vel rerum. Dolores sunt modi temporibus dolorem atque consequuntur eveniet. Et deserunt quis nostrum sed. Veritatis dolorem asperiores delectus corporis eius.

Occaecati accusantium et ea ullam excepturi et tempora. Commodi voluptatum magni impedit distinctio rerum deserunt dolore. Facere non et deserunt dicta est voluptatibus rem rem. Voluptas porro repellendus molestiae vel rem. Rem quam voluptatum ducimus laborum distinctio doloribus excepturi aut.

Sed beatae hic nihil perferendis ipsum et non tenetur. Deserunt tempore quasi et aliquid porro commodi. Quisquam error enim eius et harum explicabo sed. Officiis consequuntur fugit tempora distinctio saepe ea ut. Dicta assumenda officia voluptatibus non iusto. Sint pariatur architecto ut veritatis ab. Qui ratione occaecati molestiae laborum.

I'm an AI bot trained on the most helpful WSO content across 17+ years.

Career Advancement Opportunities

May 2024 Private Equity

  • The Riverside Company 99.5%
  • Blackstone Group 99.0%
  • Warburg Pincus 98.4%
  • KKR (Kohlberg Kravis Roberts) 97.9%
  • Bain Capital 97.4%

Overall Employee Satisfaction

May 2024 Private Equity

  • The Riverside Company 99.5%
  • Blackstone Group 98.9%
  • KKR (Kohlberg Kravis Roberts) 98.4%
  • Ardian 97.9%
  • Bain Capital 97.4%

Professional Growth Opportunities

May 2024 Private Equity

  • The Riverside Company 99.5%
  • Bain Capital 99.0%
  • Blackstone Group 98.4%
  • Warburg Pincus 97.9%
  • Starwood Capital Group 97.4%

Total Avg Compensation

May 2024 Private Equity

  • Principal (9) $653
  • Director/MD (22) $569
  • Vice President (92) $362
  • 3rd+ Year Associate (91) $281
  • 2nd Year Associate (206) $268
  • 1st Year Associate (389) $229
  • 3rd+ Year Analyst (29) $154
  • 2nd Year Analyst (83) $134
  • 1st Year Analyst (246) $122
  • Intern/Summer Associate (32) $82
  • Intern/Summer Analyst (316) $59
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”